New radiation technique aims to spare rectal cancer patients from surgery
NCT ID NCT04808323
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether MRI-guided adaptive radiation therapy, combined with the chemotherapy drug capecitabine, can safely treat rectal cancer while preserving the rectum. About 22 adults with stage I-III rectal cancer will receive escalating doses of radiation guided by real-time MRI. The main goal is to check for serious side effects, but researchers will also see if the cancer disappears completely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Capecitabine (chemotherapy) plus MRI-guided adaptive radiation therapy
What this could lead to
If successful, this approach could allow some rectal cancer patients to avoid surgery and keep their rectum, improving quality of life.
What could go wrong
This is a very early Phase 1 trial with only 22 people, focused on safety. It is too small to prove effectiveness, and there is a risk of serious side effects from the high radiation doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact